NEW YORK, June 12, 2017 /PRNewswire/ -- A new clinical trial reveals that CefalyŽ, the first FDA-approved external trigeminalnerve stimulation device for the prevention of frequent episodic migraines, has been used successfully on migraine patients who do not respond to usual oral migraine medication (refractory migraine).
The results, published in BMC Neurology,
"We're excited to offer migraineurs hope and solution when usual oral preventive medication does not work. This is a great step that confirms CefalyŽ efficacy, particularly when medication fails, which is among the most difficult demographic of patients to treat," said Dr. Pierre Rigaux, the chief executive officer of CEFALY Technology, and a member of the team that invented the device.
Migraine affects 38 million people in the U.S., according to the Migraine Research Foundation. The debilitating neurological condition impacts all aspects of a migraineur's life. Almost a third of the patients suffered more than three migraines a month and needed a migraine preventive treatment in order to reduce the frequency of the attacks. The study results confirm the high efficacy of CefalyŽ, even when other treatments didn't work. The constant accumulation of clinical data about the CefalyŽ shows clearly that CefalyŽ, offers the best safety efficacy ratio and thus is becoming the first line treatment for patients having frequently migraine attacks.
CefalyŽ, is a palm-sized, prescription-only, device that works through a self-adhesive electrode that's placed on the forehead and a magnetic connection, which sends tiny electrical impulses through the skin to the upper branches of the trigeminal nerve to desensitize the trigeminovascular system. The device, which is not yet covered by most insurance companies, costs $349 and comes with a 60-day money back guarantee. CefalyŽ is indicated for those ages 18 and older. Women who are pregnant or could become pregnant should check with their doctor before using CefalyŽ.
About CEFALYŽ TechnologyCEFALYŽ Technology is a Belgium-based company, with US offices based in Wilton, Connecticut, specializing in electronics for medical applications. It has developed external cranial stimulation technology for applications in the field of neurology; in particular for treating migraines. For more information, visit http://www.Cefaly.us. Find Cefaly on Twitter: @Cefaly, Facebook: http://www.facebook.com/CefalyEN, and YouTube: http://www.youtube.com/c/CEFALYTechnology.
Media Contact: Maria Coder 646-494-4773 firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/study-finds-migraine-device-cefaly-an-effective-treatment-for-refractory-migraine-300472076.html
SOURCE CEFALY Technology
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All